OncoSec Medical Inc (ONCSQ)

[ash111]

ONCS: Market value

There are about 15,700 patients receiving anti-PD-1 therapy for melanoma, of which about 10,200 of them are nonresponders. If ImmunoPulse IL-12 can show a 30% response rate for nonresponders, that would increase the addressable market by about 3,060 patients. At a cost of $150,000 per year, that translates to revenues of about $460 million annually. Considering that, the fact OncoSec has a market cap of only $24 million means if the registrational phase II succeeds, shares could be quickly revalued higher.

The upcoming registrational trial is open-label, so investors will be able to track results as they are reported and could get a decent idea of whether the trial will succeed or not based on interim results, which could start coming in by the beginning of 2018.

Disclosure: Long MRK, ONCS.

https://www.gurufocus.com/news/518583/merck-collaborates-with-oncosec-medical-to-unlock-untapped-market-for-keytruda-